Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
Hypertension is a major risk factor for human morbidity and mortality through its effects on target organs like heart, brain and kidneys. More intensive treatment for the effective control of blood pressure significantly reduces the morbidity and mortality. The renin angiotensin system (RAS) is a coordinated hormonal cascade of major clinical importance in the regulation of blood pressure. The principal effector peptide of RAS is angiotensin II, which acts by binding to one of the two major angiotensin II receptors AT(1) and AT(2). Angiotensin II through AT(1) receptor mediates vast majority of biologically detrimental actions. Nonpeptidic angiotensin II (AT(1)) antagonists are the most specific means to block the renin angiotensin enzymatic cascade available presently. Majority of AT(1) antagonists are based on modifications of losartan structure, the first clinically used AT(1) antagonist. In this review, a comprehensive presentation of the literature on AT(1) receptor antagonists has been given.
Pharmacy Department, Faculty of Tech. and Engg., The M. S. University of Baroda, Vadodara 390 001, Gujarat, India.
Prashant
P
Naik
Prashant
P
Murumkar
Rajani
R
Giridhar
Mange Ram
MR
Yadav
D047228:Angiotensin II Type 1 Receptor Blockers / Q000737:chemistry*; D057911:Angiotensin Receptor Antagonists / Q000737:chemistry; D000959:Antihypertensive Agents / Q000737:chemistry; D006801:Humans; D019808:Losartan / Q000737:chemistry
D047228:Angiotensin II Type 1 Receptor Blockers; D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D019808:Losartan